New mothers with HIV gain more weight on dolutegravir than efavirenz
Immune modulator clears pre-cancerous anal lesions
Black MSM are 60% less likely to have suppressed HIV than white men in Atlanta
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health
Unique transgender vulnerabilities require tailored and specific interventions
Taking PrEP during acute HIV infection for more than 2-3 weeks is likely to cause resistance, Thai study finds
Experts shed light on coronavirus response and its implications for people with HIV
SEARCH study finds universal 'test and treat' reduces infant HIV
Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity
HIV vaccine that generates broadly neutralising antibodies passes first safety and proof-of-concept study in humans
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women
Younger people with HIV lose lung function faster
One third of adolescents and young adults on ART in Kenya are not virally suppressed
No increase in HIV in blood donations since rules for gay men were relaxed
New PEP studies revive interest in post-exposure prevention
Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans
Azithromycin reduces exacerbations of HIV-related chronic lung disease in children and adolescents
Long-acting injectables might be administered every two months
